Q-omics provides the consensus-scored CERS3 profile across patient tissues and cancer cell-line models. CERS3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CERS3 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, CERS3 RNA expression shows 11,704 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight COAD, LUSC, and ESCA as cancer lineages where CERS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERS3 survival associations across molecular data types. CERS3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERS3 RNA expression–survival associations across cancer types. High CERS3 expression shows unfavorable associations in COAD, SKCM, BLCA and ACC, but favorable associations in PAAD and LUSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify COAD as the clearest survival context for CERS3 RNA expression.
This table summarizes CERS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CERS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERS3 shows lower tumor expression in BRCA, PRAD and THCA and higher tumor expression in LUSC, BLCA and KIRP. The LUSC box plot shows higher CERS3 RNA expression in tumor versus normal tissue (log2 FC = +4.121, t-test p < 0.001).
This table shows molecular features associated with CERS3 in patient tissues and cancer cell lines. In patient samples, CERS3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CERS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUSC.
